Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Charles River Laboratories Intl (CRL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,801,831
  • Shares Outstanding, K 47,360
  • Annual Sales, $ 1,681 M
  • Annual Income, $ 154,770 K
  • 36-Month Beta 0.94
  • Price/Sales 2.86
  • Price/Cash Flow 13.78
  • Price/Book 4.71

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.12 +2.29%
on 11/15/17
119.05 -14.83%
on 11/02/17
-12.84 (-11.24%)
since 10/17/17
3-Month
98.90 +2.52%
on 08/18/17
119.05 -14.83%
on 11/02/17
+1.68 (+1.68%)
since 08/17/17
52-Week
69.51 +45.86%
on 12/02/16
119.05 -14.83%
on 11/02/17
+27.68 (+37.55%)
since 11/17/16

Most Recent Stories

More News
Earnings Review and Free Research Report: Labcorp's Revenue Jumped 9.5%; Raised Outlook for 2017

Research Desk Line-up: Charles River Laboratories Post Earnings Coverage

LH : 150.36 (-0.44%)
CRL : 101.39 (-0.08%)
Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations

--- Third-Quarter GAAP EPS of $1.09 and Non-GAAP EPS of $1.30 -

CRL : 101.39 (-0.08%)
Why Earnings Season Could Be Great for Charles River Laboratories (CRL)

Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

CRL : 101.39 (-0.08%)
What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?

DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.

AMED : 55.01 (-1.50%)
MYGN : 32.88 (-1.59%)
CRL : 101.39 (-0.08%)
DVA : 54.91 (-1.31%)
Charles River Laboratories Presents Newly Expanded Capabilities at Neuroscience 2017

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts is presenting 27 scientific posters, both independently and...

CRL : 101.39 (-0.08%)
Clinical Laboratory Services Market: Companies Focus on Technological Advancements to Surge Ahead - Transparency Market Research

The global clinical laboratory services market demonstrates a largely fragmented business landscape due to the presence of a large pool of international and regional players, states a recent market intelligence...

GHDX : 28.70 (-1.17%)
DGX : 93.04 (+0.11%)
SKHCF : 16.2500 (-0.06%)
CRL : 101.39 (-0.08%)
LH : 150.36 (-0.44%)
Charles River Announces Expansion of In Vitro Oncology Services

Charles River Laboratories International, Inc. (NYSE: CRL) today announced its partnership with InSphero AG, a leading supplier of 3D solutions for in vitro drug discovery and development....

CRL : 101.39 (-0.08%)
Charles River Laboratories Changes the Date of Its Third-Quarter 2017 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) has changed the date of its third-quarter 2017 earnings release and conference call. The Company will now release financial results...

CRL : 101.39 (-0.08%)
Charles River Laboratories Schedules Third-Quarter 2017 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2017 financial results on Wednesday, November 8th, before the market opens. A conference call has been...

CRL : 101.39 (-0.08%)
Charles River Research Models in Drug Discovery Award Presented to Sonia Vallabh and Eric Minikel of the Prion Alliance

On Tuesday, September 26, 2017, James Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories International, Inc. will present the first Charles River Research...

CRL : 101.39 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader inproviding the animal research models required in research and development for new drugs,...

See More

Key Turning Points

2nd Resistance Point 102.72
1st Resistance Point 102.06
Last Price 101.39
1st Support Level 100.67
2nd Support Level 99.94

See More

52-Week High 119.05
Last Price 101.39
Fibonacci 61.8% 100.13
Fibonacci 50% 94.28
Fibonacci 38.2% 88.43
52-Week Low 69.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart